Direkt zum Inhalt
Merck
Alle Fotos(3)

Wichtige Dokumente

Gesamtdokumentation anzeigen

P1793

Sigma-Aldrich

Pimozid

≥98% (TLC), powder, D₂ dopamine receptor antagonist

Synonym(e):

1-[1-[4,4-Bis(4-fluorphenyl)-butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-on

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(3)

About This Item

Empirische Formel (Hill-System):
C28H29F2N3O
CAS-Nummer:
2062-78-4
Molekulargewicht:
461.55
EG-Nummer:
218-171-7
MDL-Nummer:
MFCD00055081
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24277923
NACRES:
NA.77

Produktbezeichnung

Pimozid,

Form

powder

Löslichkeit

DMSO: 18 mg/mL(lit.)
chloroform: 5 mg/mL
H2O: insoluble(lit.)

Ersteller

Teva

Lagertemp.

2-8°C

SMILES String

Fc1ccc(cc1)C(CCCN2CCC(CC2)N3C(=O)Nc4ccccc34)c5ccc(F)cc5

InChI

1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)

InChIKey

YVUQSNJEYSNKRX-UHFFFAOYSA-N

Angaben zum Gen

human ... ABCB1(5243) , CACNA1G(8913) , CYP3A4(1576) , DRD1(1812) , DRD2(1813) , DRD3(1814) , DRD4(1815) , DRD5(1816) , HTR2A(3356) , HTR7(3363) , KCNH1(3756) , KCNH2(3757) , OPRD1(4985)
mouse ... Abcb1a(18671) , Abcb1b(18669)
rat ... Scnn1g(24768)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

D2 dopamine receptor antagonist; binds with high affinity to the cloned 5-HT7 receptor; Ca2+ channel antagonist; antipsychotic

Leistungsmerkmale und Vorteile

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Cyclic Nucleotide-Gated (CNG) and Hyperpolarization Activated Cyclic Nucleotide-Gated (HCN) Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Teva. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H302

Gefahreneinstufungen

Acute Tox. 4 Oral

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
SLCL5647
SLCF5333
SLCC3428
SLBX0707
SLBT8468

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Junjun Chen et al.
Chemistry & biology, 18(11), 1390-1400 (2011-11-29)
Ubiquitin-specific proteases (USPs) have in recent years emerged as a promising therapeutic target class. We identified selective small-molecule inhibitors against a deubiquitinase complex, the human USP1/UAF1, through quantitative high throughput screening (qHTS) of a collection of bioactive molecules. The top
Holger H H Erb et al.
PloS one, 15(8), e0237248-e0237248 (2020-08-14)
Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour progression and
Tamara Pringsheim et al.
The Cochrane database of systematic reviews, (2)(2), CD006996-CD006996 (2009-04-17)
Neuroleptic drugs with potent D-2 receptor blocking properties have been the traditional treatment for tics caused by Tourette Syndrome. Pimozide is the most studied of these. Use of these medications is declining because of concerns about side effects, and new
Veit Roessner et al.
Neuropharmacology, 68, 143-149 (2012-06-26)
The present review gives an overview of current pharmacological treatment options of tic disorders and Tourette Syndrome (TS). After a short summary on phenomenology, clinical course and comorbid conditions we review indications for pharmacological treatment in detail. Unfortunately, standardized and
Sager J Gosai et al.
PloS one, 5(11), e15460-e15460 (2010-11-26)
The development of preclinical models amenable to live animal bioactive compound screening is an attractive approach to discovering effective pharmacological therapies for disorders caused by misfolded and aggregation-prone proteins. In general, however, live animal drug screening is labor and resource
Alle zugehörigen Dokumente anzeigen

Verwandter Inhalt

Discover Bioactive Small Molecules for Cyclic Nucleotides

Cyclic nucleotides, including cyclic AMP (cAMP), cyclic GMP (cGMP) and cyclic ADP-ribose, have been extensively studied as second messengers of intracellular events initiated by activation of GPCRs. cAMP modifies cell function in all eukaryotic cells, principally through the activation of cAMP-dependent protein kinase (PKA), but also through cAMP-gated ion channels and guanine nucleotide exchange factors directly activated by cAMP.

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.